← Leaderboards
Ridong Chen
Apt Therapeutics, Inc.
$22,072,784
Attributed
$22,072,784
Total exposure
30
Grants
30
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,072,784 · 30
By mechanism
R44$13,126,895 · 7
R43$5,946,588 · 22
SB1$2,999,301 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseBlood VesselsPreventProteinsSafetyCellsAnimalsRattusHemorrhageApyraseToxic EffectProgramsClinically RelevantAttenuatedGenerationsCell LineDesignChimeric ProteinsPrincipal InvestigatorPharmaceutical PreparationsChinese Hamster Ovary CellAnimal ModelProductionBinding Sites
Grant awards (43)
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction$1,717,926
R44 · FY2025 · HL · contact PI
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction$1,360,862
R44 · FY2024 · HL · contact PI
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction$1,582,022
R44 · FY2023 · HL · contact PI
Immunomodulatory Therapy for Neuropathic Pain$501,320
R44 · FY2023 · NS · contact PI
Immunomodulatory Therapy for Neuropathic Pain$922,476
R44 · FY2022 · NS · contact PI
Immunomodulatory Therapy for Neuropathic Pain$996,399
R44 · FY2021 · NS · contact PI
Peripherally Acting Analgesic for Osteoarthritis Pain$259,576
R43 · FY2021 · AR · contact PI
Anti-inflammatory and Anti-diabetic Therapy for Metabolic Syndrome$300,000
R43 · FY2020 · DK · contact PI
Antithrombotic Therapy with No Bleeding Risk for PCI$723,518
R44 · FY2019 · HL · contact PI
Combination treatment with tPA and IL2 analog for Stroke$344,933
R43 · FY2019 · NS · contact PI
Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody$300,000
R43 · FY2019 · CA · contact PI
Antithrombotic Therapy with No Bleeding Risk for PCI$878,319
R44 · FY2018 · HL · contact PI
Prevention of Post-MI Heart Failure with Immunomodulatory Therapy$337,602
R43 · FY2018 · HL · contact PI
Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade$299,794
R43 · FY2018 · CA · contact PI
Immunomodulatory Therapy for Neuropathic Pain$299,346
R43 · FY2018 · NS · contact PI
Human Apyrase Therapy for Acute Ischemic Stroke$262,515
SB1 · FY2018 · NS · contact PI
Human Apyrase Therapy for Acute Ischemic Stroke$1,768,629
SB1 · FY2017 · NS · contact PI
Antithrombotic Therapy with No Bleeding Risk for PCI$300,437
R44 · FY2017 · HL · contact PI
Immunomodulatory Therapy for Diabetic Nephropathy$279,040
R43 · FY2017 · DK · contact PI
Human Apyrase Therapy for Acute Ischemic Stroke$968,157
SB1 · FY2016 · NS · contact PI
IL2-based Immunotherapy for Type 2 Diabetes$299,200
R43 · FY2016 · DK · contact PI
IL2-based Immunotherapy for Lupus$225,000
R43 · FY2016 · AR · contact PI
Human Apyrase Therapy for Diabetic Neuropathic Pain$299,793
R43 · FY2015 · NS · contact PI
Optimized IL2-based Therapy for Type 1 Diabetes$298,486
R43 · FY2015 · DK · contact PI
Low-dose IL-2-based Immunomodulatory Therapy for PAH$297,410
R43 · FY2015 · HL · contact PI
Low-dose IL2-based Immunomodulatory therapy for Stroke$224,879
R43 · FY2014 · NS · contact PI
Manufacturing of Growth Factors to Enable Cardiopoietic Stem Cell Therapy for Hea$224,139
R43 · FY2014 · HL · contact PI
Adjunctive Use of Apyrase to Fibrinolytic Therapy$577,816
R44 · FY2013 · HL · contact PI
optimized Human Apyrase for Bone Cancer Pain Treatment$288,298
R43 · FY2013 · CA · contact PI
Adjunctive Use of Apyrase to Fibrinolytic Therapy$729,640
R44 · FY2012 · HL · contact PI
Prevention of Vein Graft Intimal Hyperplasia with Optimized Human Apyrase$281,598
R43 · FY2012 · HL · contact PI
Combination Treatment of tPA and Apyrase for Stroke$494,921
R44 · FY2011 · NS · contact PI
Combination Treatment of tPA and Apyrase for Stroke$98,708
R44 · FY2011 · NS · contact PI
Combination Treatment of tPA and Apyrase for Stroke$612,233
R44 · FY2010 · NS · contact PI
Apyrase to treat ischemia/reperfusion injury during lung transplantation$439,052
R44 · FY2010 · HL · contact PI
Combination Therapy of Aspirin and Apyrase for Stroke$287,622
R43 · FY2010 · NS · contact PI
Apyrase to treat ischemia/reperfusion injury during lung transplantation$400,811
R44 · FY2009 · HL · contact PI
Adjunctive Use of Apyrase to Fibrinolytic Therapy$226,120
R43 · FY2009 · HL · contact PI
Human Apyrase to Disrupt Cancer Therapy$196,745
R43 · FY2008 · CA · contact PI
Antithrombotic Effects of Optimized Human Apyrase$453,690
R44 · FY2007 · HL · contact PI
Apyrase to Treat Ischemia/Reperfusion Injury during Lung Transplantation$189,572
R43 · FY2007 · HL · contact PI
Preclinical Validation of Human Apyrase in Stroke Models$187,435
R43 · FY2007 · NS · contact PI
Antithrombotic Effects of Optimized Human Apyrase$336,745
R44 · FY2006 · HL · contact PI